An investigation of the COMT gene Val158Met polymorphism in patients admitted to the emergency department because of synthetic cannabinoid use

Nennicioglu, Y; Kaya, H; Eraybar, S; Atmaca, S; Gorukmez, O; Armagan, E

doi:10.2478/bjmg-2020-0010

Abstract

Catechol-O-methyl transferase (COMT) enzyme has a role in the inactivation of catecholamine neurotransmitters. Functional polymorphism in the COMT gene has been reported to play an important role in schizophrenia, bipolar affective disorder, aggressive and antisocial behavior, suicide attempts and the pathogenesis of Parkinson’s disease. In this study, we aimed to investigate the effect of the Vall58Met polymorphism of the COMT gene on substance use, and treatment history in patients with synthetic cannabinoid (SC) intoxication. The COMT enzyme Val158Met polymorphisms from DNA of 49 patients who were evaluated in the Emergency Department after SC use and 50 healthy control groups aged 18-45 years, were identified by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses as reported in the literature. Information regarding recurrent intake or hospitalization due to substance use was obtained from hospital records. Wild-type (WT) genotypes in 14 (28.6%) patients, heterozygous genotypes in 25 (51.0%) and homozygous genotypes in 10 (20.4%) patients were detected. Wild-type genotypes The homozygous genotype was found to be significantly higher in patients hospitalized due to drug addiction and substance use (p 0.008). The Vall58 Met polymorphism of the COMT gene was not found to be significant in the first use after substance intake, while a significant relationship was found in terms of this polymorphism in patients with substance addiction diagnosis and treatment history.

References

Williams HJ, Owen MJ, O’Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull. 2007; 33(3): 635-461.
Search in Google Scholar Back to article
Varma GS, Karadağ OF, Erdal ME, Ay Öİ, Levent N, Tekkanat Ç, et al. Katekol-O-metiltransferaz geni Vall58 Met polimorfizminin şizofreni hastalarındaki bilişsel işlevlere Tiileri. Bull Clin Psychopharmacol. 2011; 21(1): 24-32.
Search in Google Scholar Back to article
Oswald LM, McCaul M, Choi L, Yang X, Wand GS. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: A preliminary report. Biol Psychiatry. 2004; 55(1): 102-105.
Search in Google Scholar Back to article
Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, et al. Catechol O-methyltransferase val 15 8met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry. 2006; 63(12): 1396-1406.
Search in Google Scholar Back to article
van Winkel R, Henquet C, Rosa A, Papiol S, Fañanás L, De Heret M, et al. Evidence that the COMT Val158 Met polymorphism moderates sensitivity to stress in psychosis: An experience sampling study. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(1): 10-17.
Search in Google Scholar Back to article
Stein MB, Fallin MD, Schork NJ, Gelernter J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology. 2005; 30(11): 2092-2102.
Search in Google Scholar Back to article
Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend. 2013; 130(1-3): 68-76.
Search in Google Scholar Back to article
Crime UNOoDa. World Drug Report 2017: United Nations publication. Available from: https://www.unodc.org/wdr2017/index.html
Search in Google Scholar Back to article
Tomiyama K, Funada M. Cytotoxicity of synthetic cannabinoids found in “Spice” products: The role of can-nabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol Lett. 2011; 207(1): 12-17.
Search in Google Scholar Back to article
Su MK, Seely KA, Moran JH, Hoffman RS. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther. 2015; 97(6): 562-564.
Search in Google Scholar Back to article
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014; 144: 12-41.
Search in Google Scholar Back to article
Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012; 120(1-3): 238-241.
Search in Google Scholar Back to article
Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.
Search in Google Scholar Back to article
Johnson LA, Johnson RL, Alfonzo C. Spice: A legal marijuana equivalent. Mil Med. 2011; 176(6): 718-720.
Search in Google Scholar Back to article
Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013; 32(2): 141-146.
Search in Google Scholar Back to article
Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012; 60(4): 435-438.
Search in Google Scholar Back to article
Evren C, Ögel K. Alkol/madde bagimlilarinda dissosiyatif belirtiler ve çocukluk çagi travmasi, depresyon, anksiyete ve alkol/madde kullanimi ile iliskisi. (Dis-sociative symptoms among alcohol and substance dependents and its relationships with childhood trauma history, depression, anxiety, and alcohol/substance use.) Anatolian J Psychiatry. 2003; 4(1): 30.
Search in Google Scholar Back to article
Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA. 1997; 94(9): 4572-4575.
Search in Google Scholar Back to article
Klemetsdal B, Straume B, Giverhaug T, Aarbakke J. Low catechol-O-methyltransferase activity in a Saami population. Eur J Clin Pharmacol. 1994; 46(3): 231-235.
Search in Google Scholar Back to article
Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001; 98(12): 6917-6922.
Search in Google Scholar Back to article
Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6(3): 243-250.
Search in Google Scholar Back to article
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004; 75(5): 807-821.
Search in Google Scholar Back to article
Tunbridge E, Weickert C, Kleinman J, Herman M, Chen J, Kolachana B, et al. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex. 2007; 17(5): 1206-1212.
Search in Google Scholar Back to article
Craddock N, O’Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull. 2006; 32(1): 9-16.
Search in Google Scholar Back to article

An investigation of the COMT gene Val158Met polymorphism in patients admitted to the emergency department because of synthetic cannabinoid use

Abstract

Paradigm

My account